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This article is an update of the requirements of a specialist breast centre, produced by EUSOMA and
endorsed by ECCO as part of Essential Requirements for Quality Cancer Care (ERQCC) programme, and
ESMO.
To meet aspirations for comprehensive cancer control, healthcare organisations must consider the
requirements in this article, paying particular attention to multidisciplinarity and patient-centred
pathways from diagnosis, to treatment, to survivorship.it (L. Biganzoli).
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ECCO as part of Essential Requirements for
Quality Cancer Care (ERQCC) programme,
and ESMO. The centrepiece of this article is the requirements section, comprising definitions; multi-
disciplinary structure; minimum case, procedure and staffing volumes; and detailed de-
scriptions of the skills of, and resources needed by, members and specialisms in the
multidisciplinary team in a breast centre.
 These requirements are positioned within narrative on European breast cancer epidemi-
ology, the standard of care, challenges to delivering this standard, and supporting evidence,
to enable a broad audience to appreciate the importance of establishing these requirements
in specialist breast centres.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction: The need for quality frameworks
There has been a growing emphasis on driving up quality in
cancer organisations in order to optimise patients outcomes. The
European Cancer Concord (ECC), a partnership of patients, advo-
cates and cancer professionals, has recognised major disparities in
the quality of cancer management and in the degree of funding in
Europe, and has launched a European Cancer Patient’s Bill of Rights,
a patient charter that underpins equitable access to optimal cancer
control, cancer care and research for Europe’s citizens [1]. (see
Figs. 1 and 2).
It follows an assessment of the quality of cancer care in Europe
as part of the first EU Joint Action on Cancer, the European Part-
nership for Action Against Cancer (EPAAC, http://www.epaac.eu),
which reported in 2014 that there are important variations in ser-
vice delivery between and within countries, with repercussions in
quality of care. Factors such as waiting times and provision of
optimal treatment can explain about a third of the differences in
cancer survival, while lack of cancer plans, for example a national
cancer plan that promotes clinical guidelines, professional training
and quality control measures, may be responsible for a quarter of
the survival differences.
The EU Joint Action on Cancer Control (CANCON), which
replaced EPAAC from 2014, also focused on quality of cancer care
and in 2017 published the European Guide on Quality Improvement
in Comprehensive Cancer Control. [2] This recognised that many
cancer patients are treated in general hospitals and not in
comprehensive cancer centres (CCCs) and explores a model of
‘comprehensive cancer care networks’ that can integrate expertise
under a single governance structure. Research also shows that care
provided by multidisciplinary teams (MDTs) result in better clinical
and organisational outcomes for patients [3].
Countries have been concentrating expertise for certain tumour
types in such networks and in dedicated centres, or units, such as
for childhood and rare cancers, and all CCCs have teams for the
main cancer types. For common adult tumours, however, at the
European level there has been widespread effort to establish uni-
versal, dedicated units only for breast cancer, following several
European declarations that set a target of the year 2016 for care of
all women and men with breast cancer to be delivered in specialist
multidisciplinary centres.While this target was not met, as detailed
in a European Breast Cancer Council manifesto calling for universal
breast unitsa [4], the view of the ERQCC expert group is that
healthcare systems must strive to adopt the principles of such
dedicated care for all types of cancer.1.1. Breast cancer
There is a 20-year history in Europe of calling for, and devel-
oping, specialist breast cancer units. In the year 2000, the European
Society of Breast Cancer Specialists (EUSOMA) published a positionpaper, ‘The requirements of a specialist breast unit’, which was the
first to set out standards for establishing high-quality breast cancer
centres or units across Europe [5]. The paper followed a consensus
statement drawn up at the first European Breast Cancer Conference
in Florence in 1998 that demanded that, ‘Those responsible for
organising and funding breast cancer care ensure that all women have
access to fully equipped multidisciplinary and multiprofessional breast
clinics based on population numbers of around 250,000.’ [6] The
statement was based on a growing body of evidence that optimal
care for breast cancer patients can only be obtained by an MDT,
preferably based at one location.
In the following years, European Parliament resolutions and
declarations have called for universal breast cancer units or centres
in Europe [7,8], while a number of papers and documents have
developed quality standards and EUSOMA has refined the re-
quirements [9], which were also included in the European Guide-
lines for Quality Assurance in Breast Cancer Screening and
Diagnosis [10].
This paper is an update of the EUSOMA requirements paper,
endorsed by the European CanCer Organisation (ECCO) as part of its
Essential Requirements for Quality Cancer Care (ERQCC) pro-
gramme, and by the European Society of Medical Oncology (ESMO).
This update has a wider quality context, adding narrative on
epidemiology, challenges in breast cancer care, and quality and
audit processes and examples, in addition to the components of a
breast centre. It is based on the changes in organisation and care
over the past 5 years as detailed by representatives of the disci-
plines working in breast cancer care.
The definition of the breast centre (or unit) that applies
throughout this paper is: The place where breast cancer is diag-
nosed and treated; it has to provide all the services necessary, from
genetics and prevention, through the treatment of the primary
tumour, to care of advanced disease, supportive and palliative care
and survivorship, and psychosocial support.2. Breast cancer: Key facts and challenges
2.1. Key facts
2.1.1. Epidemiology
 Breast cancer is the most common cancer in women in the Eu-
ropean Union and a rare cancer in men. It comprises a wide
range of histopathological subtypes, the most common being
invasive carcinoma of no special type (NST), previously named
invasive ductal carcinoma, and invasive lobular carcinoma [11].
Much less common are all the other histological subtypes.
Ductal carcinoma in situ (DCIS), where cancer cells are only in
the glandular tree, is a pre-malignant condition that may lead to
invasive breast cancer. Nowadays, breast cancer is also classified
intomolecular subtypes, namely luminal A and B, HER2-positive
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subtypes are mainly used in clinical practice e hormone re-
ceptor and HER2 receptor status, and a proliferation measure
(usually Ki67). Oestrogen-positive (ERþ)/HER2-negative breast
cancer is the most common subtype, comprising about 70% of
cases.
 Breast cancer incidence varies across European countries but
overall the lifetime risk is about 1 in 10 for women. Breast cancer
is a substantial health burden on society, and has been esti-
mated to cost about 13% of the total cancer healthcare costs in
the EU, the highest of any cancer, and second in overall eco-
nomic burden after lung cancer [12]. The estimated incidence of
breast cancer in 2018 in Europe (EU 28 þ European Free Trade
Association (EFTA) countries) was about 416,000 with a Euro-
pean age standardised rate of 145/100,000) [13]. Estimated
incidence was highest in Belgium (204/100,000), Luxembourg
and the Netherlands, the lowest in Romania (90/100,000) and
Poland; generally, incidence is lower in Southern and Eastern
Europe, but data from these countries might be incomplete due
to issues with cancer registries. Estimated mortality in 2018 was
about 100,000, with the highest European age standardised
rates in Croatia (43/100,000), Iceland and Ireland, and the
lowest in Spain (23/100,000), Finland and Norway (see Fig. 1).
 There are high survival rates for breast cancer in Europe. The
EUROCARE-5 study, the latest in the series, reports the 5-year
relative survival rate in 2000e2007 at 82%, ranging from 74%
(Eastern Europe) to 85% (Northern Europe), and survival
increased during the study period [14]. Survival was uniformly
higher for women in countries with population breast cancer
screening. The 5-year relative survival was highest in the 45e54
and 55e64 year age groups and declined in older patients.
 Breast cancer mortality rates have declined in the European
Union and are predicted to fall further, with the largest falls in
young women (20e49 years, 22% between 2002 and 2012)
[15]. The fall in mortality is said to be mainly due to improve-
ments in the management and treatment of breast cancer,
although early diagnosis and screening are also important.Fig. 1. European breast cancer mortality and incidence
Source: European Cancer Information System. European age standardised rates.Improving breast cancer management in Central and Eastern
Europe is a particular priority [15].
 It is important to note that there has been little progress in
extending the median survival of patients with advanced or
metastatic (stage 4) breast cancer, which remains at about 3
years, although longer survival may be seen particularly in the
HER2-positive subtype [16e18].2.1.2. Risk factors
 Risk factors for breast cancer inwomen include older age, family
history, previous benign breast disease, and a previous breast
cancer diagnosis. In addition, several hormonal factors, partic-
ularly those that exposewomen tomoremenstrual cycles, play a
role in increasing risk, including early menstrual periods, late
menopause, less (and later) childbirths and less breast feeding.
 Pathological germline variants in the BRCA1/2 genes can greatly
increase risk; other gene variants can also add variable risk.
Womenwith dense breasts are more likely to be diagnosed with
breast cancer.
 Preventable risk factors include overweight/obesity, lack of
physical activity, smoking and alcohol consumption. Hormonal
replacement therapy increases risk. Women who have had ra-
diation therapy to the chest or breast as treatment for other
cancers (i.e. lymphoma) are also at increased risk.
 Risk factors for breast cancer in men include older age, family
history, BRCA1/2 variants (especially in BRCA2), gynecomastia,
heavy alcohol intake, liver disease, obesity and radiation
exposure.2.1.3. Diagnosis and treatment
Note key ESMO and ESO-ESMO guideline references for diagnosis,
treatment and care of early breast cancer [19] and advanced breast
cancer. [20].
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evidence for the benefit of population screening (cervical and
colorectal are the other two) and most European countries have
introduced mammographic screening programmes, most
commonly screening women between the ages of 50 and 70 at 2
year intervals to primarily detect small tumours that cause no
symptoms. However, about an equivalent number of breast
cancers are detected by self-examination for breast lumps and
other symptoms including a change in the size or shape of a
breast, dimpling of skin, inverted nipple, nipple rash and
discharge, and a swelling or lump in the armpit. Ductal carci-
noma in situ (DCIS), which is a non-invasive pre-malignant
condition, may be asymptomatic or associated with a lump and
is detected by mammography (usually through the presence of
abnormal microcalcifications).
 Diagnosis should be made by a ‘triple assessment’, comprising
clinical assessment (patient history and physical examination),
mammography and/or ultrasound imaging, and a biopsy (a core
needle biopsy is necessary; a fine-needle aspiration (FNA) is
insufficient and should not be performed in the breast, since it
has a high rate of false results and does not allow for adequate
biomarker characterisation). Ultrasound is also used to image
the axilla (armpit area) for affected lymph nodes, as a common
site of spread are ipsilateral axillary nodes, and a biopsy/FNA
taken if involvement is suspected; if not suspected, to rule out
spread to the nodes, sentinel lymph node biopsy (SLNB) is a
surgical procedure that has become the standard of care to
identify the first node(s) that could be involved in early breast
cancer. Breast cancer is commonly staged according to the TNM
system and graded for cell differentiation (nuclear atypia and
proliferation) and tubule formation. All invasive breast cancer
should be assessed for ER, progesterone (PgR) and HER2 re-
ceptor status. The distinction between low and high-grade DCIS
and invasive cancer is also important.
 Genetic testing for the BRCA 1/2 mutations is recommended in
certain cases as it has implications for clinical management [21].
 Early invasive and locally advanced breast cancer are treated
with curative intent. Local treatments include surgery (breast-
conserving surgery (BCS) or mastectomy with sentinel lymph
node biopsy or axillary dissection) and radiation therapy. Sys-
temic therapy options include chemotherapy, endocrine ther-
apy, HER2 targeted therapy and bisphosphonates, according to
risk of relapse and receptor status, and can be offered before
(primary systemic therapy, also known as neoadjuvant or pre-
operative) and/or after surgery (adjuvant therapy).
 Primary systemic therapy is being used increasingly in higher
risk biological subtypes (e.g. triple negative and HER2-positive)
even in cases where BCS would be possible upfront, since this
strategy enables personalisation of therapy based on response
and facilitates prediction of prognosis for individuals based on
pathological response. Primary systemic therapy is the recom-
mended strategy for locally advanced breast cancer and in-
flammatory breast cancer. For locally advanced disease, surgical
treatment varies depending on characteristics at diagnosis and
response to therapy, while for inflammatory breast cancer,
mastectomy and axillary dissection, followed by radiation
therapy, is usually necessary even in the presence of a good
response to primary systemic therapy.
 Tamoxifen and aromatase inhibitors are approved endocrine
agents for ER þ early breast cancer. Ovarian ablation (removal of
the ovaries) or suppression of oestrogenwith drugs may also be
offered to some premenopausal women with ER þ cancer.
 BCS followed by breast irradiation (plus endocrine therapy in
some cases) is the preferred treatment for most DCIS patients,
though widespread DCIS may well require treatment bymastectomy. Radiotherapy may be avoided in selected cases, i.e.
low grade DCIS.
 Mastectomy or BCS with sentinel lymph node biopsy or axillary
dissection and a similar range of medical and radiation therapy
options are used for male breast cancer. Aromatase inhibitors
alone should not be used for early breast cancer in male patients
[22].
 Systemic therapy with endocrine therapy, chemotherapy and
targeted therapy is the strategy of choice in advanced/meta-
static breast cancer. The choice of systemic therapy depends on
many factors, including the biology of the tumour, the burden of
metastatic disease, symptoms, performance status, comorbid-
ities, socioeconomic factors and patient preferences. Early and
continuous appropriate supportive, palliative and psychosocial
support are indispensable throughout the management of
advanced/metastatic disease.
 Surgery, radiation therapy and interventional radiology are
important to treat certain conditions, such as brain or bone
metastases, to prevent bone fractures and relieve pain. In highly
selected de novo (i.e. diagnosed already as stage 4 metastatic
cases, locoregional therapy of the primary tumour, with surgery
and/or radiation therapy, may also be performed.2.2. Challenges in breast cancer care
2.2.1. Screening and detection
 Mammography screening services are often separate from
breast treatment centres, missing opportunities for multi-
professional working in assessment and diagnosis.
 There has been wide publicity given to controversy about the
benefits and harms of population-based mammography
screening, which is one of the flagship health screening pro-
grammes in many countries. Womenmust be given information
that allows them to make informed choices about participation
in these programmes.
 Education on breast health awareness is often lacking in coun-
tries and should target girls at school as well as adult women.
 In view of exponential increase in cancer incidence, primary
care physicians must be involved in many steps of the cancer
journey, starting with screening and early diagnosis [23]. It is
essential to promote close collaboration between these spe-
cialists and breast centres for a fast referral.2.2.2. Staging and grading
 There are concerns about the quality of breast cancer pathology
services in Europe:
e They can vary to a considerable extent in the accuracy of
assessing parameters important for treatment decision-
making; few countries are monitoring and assessing this
variability
e Most pathology departments are general and may lack pa-
thologists experienced in the increasingly complex area of
breast pathology and may also lack sufficient volume of cases
to develop and maintain expertise
e In many countries there is a shortage of pathologists.
e Availability of intra-operative pathology assessment is crucial
to substantially decrease the rate of re-interventions.
A manifesto by the European Breast Cancer Council addressed
these concerns [24].
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 Awide range of shortcomings and challenges in care result from
a lack of multidisciplinary breast centres:
e Overtreatment in all areas (surgery, radiation and medical
therapies), often related to outdated reimbursement rules
e Underuse of treatments such as primary systemic therapy
e Lack of surgical expertise and experience has led to too many
mastectomies, toomany axillary dissections and toomany re-
interventions
e Lack of expertise and experience in breast radiation and
medical therapies
e Lack of oncoplastic/reconstructive expertise.
 Choosing the right treatment among an increasingly complex
range of options has become a major challenge for patients and
it is important that balanced advice is given by all breast
specialists.
 There is a lack of dedicated breast nurses and patient navigators
who can help guide patients through this complex pare
pathway. Breast care nurses are in place in only a few European
countries at present. Developing breast care nursing is impor-
tant to offer optimised care for patients [25,26] and studies have
shown that specialist nurses improve patient outcomes [27,28].
They are essential members of the core MDT.
 There is a lack of adequate supportive and psychological sup-
port. About one third of breast cancer patients experience high
levels of emotional distress [29e31], and about half report
increased levels of depression and anxiety in the year after
diagnosis [32].
 Side-effects from treatments are often not adequately managed.
 There is a lack of data on treatment of older patients and very
young patients. Although about 20% of breast cancer occurs in
patients 75 years old or older, there is a lack of data on man-
agement of older patients, especially those who are frail and
vulnerable. Chronological age alone must not be used to with-
hold effective therapies [33].2.2.4. Advanced breast cancer (includes inoperable locally
advanced and metastatic breast cancer) e treatment and support
 In Europe, most advanced breast cancer patients are still treated
outside of MDTs, by medical oncologists alone. Treating
advanced disease in specialised breast units/centres increases
access to treatment according to international guidelines, loco-
regional management of certain types of metastases, correct
management of symptoms and side-effects of therapies, inclu-
sion in clinical trials, and early links to psychosocial supportive
and palliative care, all of which are associated with higher
quality of care and improved outcomes.
 Treatment is complex, can be costly, and often involves multiple
lines of therapy with periods of good quality of life between
treatment spells, with several agents approved in recent years.
Issues of accessibility to optimal treatment options (e.g. cancer
medicines, radiation therapy) are crucial and access is highly
uneven between countries and within each country (see 2.2.7
Inequalities, below). Management of advanced disease in breast
centres can centralise and optimise access in a cost-effective
manner.2.2.5. Support services and survivorship
 Many breast cancer patients are of working age or have de-
pendants or children and may suffer financial loss as a result oftreatment related incapacity. Social support to aid in financial
and other difficulties may be required but hard to obtain.
 Services are often also required to help manage secondary ef-
fects from treatments that affect quality of life, such as physio-
therapy and occupational therapy (rehabilitation), nutritional
counselling and psycho-oncology, but there may be gaps in
provision, particularly when these services are best delivered in
the community in partnership with breast centres.
 As more patients are being diagnosed at a fertile age, and before
they have completed their families, fertility preservation is
crucial and should be part of the breast centre’s services.
 Advanced breast cancer patients face a range of survivorship
issues such as isolation, lack of information and financial
hardship.2.2.6. Genetic testing
 There are well-established protocols for testing women at high
risk of breast cancer, such as Ashkenazi Jews or those with many
affected family members for variants of the BRCA1/2 genes, but
there is rapidly developing research on lesser risk genes and also
in the most common genetic variants, SNPs [21,34]. The rapid
rise in commercial tests and in research on genetic breast cancer
risk is placing pressure on clinical genetics services and on the
knowledge base of other health professionals.
 In particular, there is a major challenge in uncontrolled and sub-
standard tests that can raise anxiety and raise demand for
counselling, and even lead to unnecessary treatment, as set out
in the 2018 European Breast Cancer Council manifesto [35].2.2.7. Inequalities
 Women with higher socioeconomic status in Europe have a
higher breast cancer incidence but lower mortality thanwomen
in lower status groups [36]. While higher incidence is linked to
reproductive factors, hormonal replacement therapy and higher
use of opportunistic screening, lower fatality seems to be
explained by earlier stage of diagnosis, and access to optimal
treatment. A report from England also shows that socio-
economically advantaged women are more likely to be diag-
nosed with breast cancer, and finds that there are geographical
variations, as women living in disadvantaged areas are more
likely to be diagnosed at a later stage with a lower chance of
survival [37].
 The same report from England also found inequalities related to
black and ethnic minority status, which are also likely to be seen
in other parts of Europe [37].
 There is evidence than many older women (over 70) are not
offered the same standard of care as younger patients despite
being eligible for treatment (see for example the National Audit
for Breast Cancer in Older Patients (NABCOP) on services in
England and Wales e (https://www.nabcop.org.uk). They are
also more likely to be diagnosed at a later stage.
 There is also evidence that quality of care for male patients with
breast cancer is lower than for their female counterparts [38].
 There are substantial inequalities in access to treatment among
and within European countries. Some Eastern European coun-
tries, especially, have shortcomings in radiation therapy and
drug availability, including inexpensive breast cancer drugs such
as tamoxifen as well as expensive new therapies, some of which
are listed by WHO as essential medicines, although lack of ac-
cess could be due to organisational and not only financial con-
straints. The use of international guidelines (which recommend
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benefit and prioritise effective therapies (such as the ESMO
Magnitude of Clinical Benefit Scale) [39] are potential solutions.
The shortage of cancer medicines was highlighted in a report
from the Economist Intelligence Unit in collaboration with
ESMO, and needs to be urgently tackled [40].2.2.8. Research
 Conducting research, in particular clinical research, is associated
with better outcomes for patients and should be included in the
services provided by the breast centre. Currently, clinical
research in some European countries is oriented towards in-
dustry sponsored studies, especially those funded by pharma-
ceutical companies, and academic research must be supported
by independent sources of funding, as called for by the Clinical
Academic Cancer Research Forum [41].
 Evidence suggests that clinical research in Europe is not ori-
ented towards investigation of antineoplastic drugs effect on
endpoints that are most important to patients (i.e. improve-
ments in quality of life, reduction of risk of recurrence for the
early stages of the disease, and life prolongation for advanced
disease) [42]. Therefore, a cornerstone of research should be to
investigate the impact of intervention on endpoints that are
patient oriented. In addition, clinical research should provide
evidence of interventions’ efficacy and safety from real life data,
to confirm/question results from clinical trials.
 Important research topics in breast cancer include [43].
e Earlier diagnosis, apart from screening
e Novel methodology with adaptive trial designs within plat-
forms and validation of novel biomarkers of early response
e Predictive factors and therapy individualisation
e Escalation and de-escalation of therapy in early breast cancer
e Identification of treatment strategies that optimise patients’
quality of life without loss of quantity.
 There is an urgent need to increase research in patient groups
that are under-represented and under-researched in breast
cancer studies, particularly older and young women, and men.
 There is a pressing need for the development and incorporation
of patient reported outcomes/measures (PROs/PROMs), and
research on quality of life and survivorship.
 Patient advocacy groups are valuable partners in all aspects of
breast cancer research, from epidemiology to treatments to
survivorship, and should be involved in all stages of research.2.2.9. Cancer registration and data availability
 Cancer registration practice, coverage and quality are highly
unequal across Europe [44]. Consequently, basic epidemiolog-
ical data on incidence, mortality and survival are not uniformly
available for all countries. Also, only a minority of cancer reg-
istries can provide sufficient data for the calculation of param-
eters necessary for the assessment of outcomes and quality of
care [45].
 A particular shortcoming in breast cancer is that few cancer
registries collect data on recurrences, including distant, which
means that there are only estimates of the number of patients
living with incurable disease. This makes it hard for healthcare
services and wider society to allocate resources for one of the
largest populations of advanced cancer patients.
 There is a need to find ways of improving quality of nationally/
internationally collected routine data so it can be embedded
within clinical trials as outcome data. Cancer registries in Europe should be compatible with each
other to analyse data collectively.
 Registries and/or other forms of real-world data should include
data on the effects on treatment outcomes of the use of OTC
(over the counter) medicines or CAM (complementary alterna-
tive medicines), which are commonly used by cancer patients
[46].
 In addition, registries and/or other forms of real-world data
should allow for the assessment of the true benefit of cancer
therapies, evaluating whether results from clinical trials are
translated into the real-life setting for efficacy and safety. This
could also benefit the evaluation of efficacy and safety profile of
the population unrepresented in randomised clinical trials.3. Breast centre: Definitions
Breast centre: The place where breast cancer is diagnosed and
treated. It has to provide all the services necessary, from genetics
and prevention, through the treatment of the primary tumour, to
care of advanced disease, supportive and palliative care, survivor-
ship and psychosocial support.
The breast centre comprises a group of dedicated breast cancer
specialists working together as a multidisciplinary team (MDT)
with access to all the facilities required to deliver high-quality care
throughout the breast cancer pathway.
Preferably, all services should be in the same facility, limiting to
a minimum the need for the patient to travel between locations.
Therefore breast centres are encouraged to be organised in one
location. However, when for organisational reasons this is not
possible, some services may be based at different locations but
must be in the same geographical area, and protocols must be in
place for the optimal integration of care, guaranteeing multidisci-
plinary work and timely access, and all sites must share the same
database for quality assurance and research.
Protocols: Official procedures or systems of rules, including
local organisational aspects, for the diagnosis and management of
breast cancer at all stages, including surveillance and long-term
follow-up.
Breast data audit: Evaluation of quality indicators to identify
corrective actions through multidisciplinary discussion.
Formal internal reviewmeeting: Evaluation of performance on
quality indicators, organisational and clinical aspects, audit results,
identification and implementation of corrective actions.
Breast multidisciplinary meeting (MDM): Where the core
MDT meets to evaluate and plan patient care at any step of the
diagnostic and treatment process.
Breast clinic: A session at which a number of breast patients are
seen for clinical examination and/or investigations, counselling, etc.
Breast specialist: A person certified in her/his own discipline
and fully trained in management of breast cancer.
Breast core MDT members: Breast specialists who are essential
for diagnosis and care of breast cancer, who spend the majority of
their working time in breast cancer and who must participate in
MDM (except for radiographers, who are part of core team but are
not requested to attend the MDM). These specialisms are detailed
in the essential requirements in section 5:
 Breast radiologist: board-certified specialist in imaging with
expertise in breast cancer diagnosis (including diagnostic
interventional procedures), further assessment and follow-up
 Breast radiographer: technician specialised in breast imaging
examination
 Breast pathologist: board-certified pathologist with expertise
in breast disease
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breast surgery including oncoplastic procedures. In some centres
this role may be shared by a breast cancer surgeon and a recon-
structive surgeon working together.
 Breast medical oncologist: board-certified medical oncologist
with expertise in breast cancer. In some countries (e.g. Ger-
many), systemic therapy for breast cancer patients is currently
delivered by organ specialists such as gynaecologists, but the
goal is that, in the near future, systemic therapy is only delivered
by medical oncologists. It is crucial that any specialist who now
delivers systemic therapy has training defined by the ESMO-
ASCO Global Curriculum for Medical Oncology [47].
 Breast radiation oncologist: board-certified radiation oncolo-
gist with expertise in breast cancer or
Breast clinical oncologist: in some countries (such as the
Nordics and the UK) clinical oncologists are professionals who are
board-certified in both radiation and medical treatments, but must
be dedicated to breast cancer.
 Breast care nurse: a nurse with specialist training in breast care
nursing
 Breast data manager: person responsible for breast cancer data
management (detailed in section 4.10).
Extended MTD members: Specialists who are consulted during
breast cancer care and treatment, but are not routinely involved in
breast cancer care for every patient. These specialisms are detailed
in the essential requirements in section 6:
 Psycho-oncologist: professional who identifies distress and
psychological morbidity and provides psychological in-
terventions to breast cancer patients and their families
 Geriatric oncologist/geriatrician: geriatrician with cancer
expertise who applies geriatric assessment for appropriate
treatment
 Oncology pharmacist: pharmacist with expertise in cancer
medicines
 Nuclear medicine physician: board-certified nuclear medicine
specialist with expertise in the management of breast cancer
patients, including sentinel lymph-node technique, molecular
imaging and theranostics
 Physiotherapist: professional who provides physical support of
patients after breast cancer therapies (breast surgery and
radiotherapy)
 Plastic surgeon: board-certified plastic surgeon with expertise
in breast reconstruction techniques
 Interventional radiologist: board certified specialist who
carries out interventional radiology techniques, such as biopsies
of metastatic lesions and local management of some types of
breast cancer metastases such as bone metastases
 Self-image professional: a specialist in breast or hair prosthesis
 Palliative care specialist: specialist who provides physical,
psychosocial and spiritual care to patients who have, or may
soon have, severe symptoms and distress from advanced disease
 Clinical geneticist: medical specialist concerned with the
assessment of genetic risk and counselling for individuals and
families with increased risk of breast cancer
 Primary prevention professionals: specialists with expertise in
physical exercise, diet and lifestyle counselling.
All members of the breast centre should have knowledge and
skills to provide basic psychological care and screen for distress.
Qualified care providers other than nurses (e.g. radiationtechnologists) also provide links between patients and the breast
team.
To guarantee the availability of other specialists who may be
needed for consultations during a breast cancer patient’s care
pathway, such as nutritionists, fertility preservation experts, car-
diologists, gynaecologists, neuro-surgeons, orthopaedic surgeons
etc., the breast centremust have establishedworking arrangements
which allow immediate and effective consultation.4. Breast centre requirements
4.1. Breast centre
There must be a formal document (that complies with any na-
tional regulations) which describes organisation of the breast
centre and which could include its relationship within the wider
cancer infrastructure such as the cancer centre and regional cancer
network (see Fig. 2).4.2. Critical mass
 A breast centre must be of sufficient size to manage at least 150
[48e50] newly diagnosed cases of early breast cancer (all
ages, based on surgery) coming under its care each year [6]. The
breast centre must also treat at least 50 cases of metastatic
breast cancer a year, independently from the line of treatment.
 The minimum number is necessary to ensure a caseload
sufficient to maintain expertise for each team member and to
ensure cost-effective working of the breast centre [50e52].
There is good quality data that shows that breast cancer survival
is related to the number of cases treated per annum (see also
supporting evidence in Appendix 1, section 1.1.).
 Minimum caseload for core MDT members:
Breast radiologist: 1000 mammographic exams (5000 for
breast radiologists participating in a centralised screening
programme), 200 breast ultrasounds and 50 magnetic reso-
nance imaging (MRI) studies and 50 breast guided in-
terventions per year
Breast radiographer: 1000 mammograms per year
Breast pathologist: 50 preoperative samples and 50 primary
breast cancer resections per year; should report on 25 met-
astatic breast surgical specimens (biopsy performed for
suspicious metastasis) per year
Breast surgeon: 50 primary breast surgeries per year
Breast medical oncologist: 50 early and 25 metastatic breast
cancer patients treated per year
Breast radiation oncologist: 50 early breast cancer patients
treated per year
Breast nurse: 50 early and 25 metastatic breast cancer pa-
tients cared for per year.4.3. Screening
 Where a population-based breast cancer screening programme
exists, the breast centre and the screening programme should
coordinate the assessment of screen-positive cases to ensure
quality and continuity of care and optimisation of resources.
 It is recommended that diagnostic assessment of screen-
detected imaging findings is done in the breast centre.
 The breast centre should contribute to improving protocols and
professional expertise at screening centres.
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 The breast centre must develop a patient pathway that ensures
continuity of care and describes the steps and their timing from
diagnosis (or screening) to follow-up including advanced dis-
ease, palliative care and end of life. This pathway must be
backed up by evidence-based protocols between care providers
which guarantee the continuity of care.
 The breast centre must identify the guidelines (national and/or
international) from which to develop the patient pathway and
internal protocols must be formally reviewed at least on an
annual basis at the formal internal review meeting.
 The patient pathway must be agreed at least by the core MDT
members but preferably also by extended team members.4.5. MDT meeting (MDM)
The breast centre must hold at least weekly a multidisciplinary
case management meeting (MDM) to discuss diagnostic preoper-
ative and postoperative cases, as well as any other issues related to
breast cancer patients that requires multidisciplinary discussion.
Advanced breast cancer cases must also be discussed.
 At least 95% of all early and locally advanced breast cancer cases
and at least 50% of metastatic cases must be discussed at the
meeting (but in future the goal is that all cases, early and met-
astatic, are discussed at the MDM). At pre-operative stage, the
MDM must consider patient-related factors, tumour-related
factors, and treatment options.
 Team members who must be present:
e Discussion of pre-operative breast cancer cases: radiologist,
pathologist, medical oncologist, surgeon, radiation oncolo-
gist, breast nurse and breast data manager
e Discussion of post-operative cases: pathologist, surgeon,
medical oncologist, radiation oncologist, breast nurse and
breast data manager
e Discussion of metastatic breast cancer cases: medical oncolo-
gist, radiation oncologist, breast nurse, radiologist, patholo-
gist, nuclear medicine physician (mandatory if the breast
centre performs and uses positron emission tomography-
computed tomography (PET-CT) and recommended if the
nuclear medicine service is not inside the hospital), palliative
care specialist and breast data manager.
 Other teammembersmust be encouraged to attend andmust be
available for consultation.
 Other specialists must be involved if necessary to discuss the
clinical situation of patients.
 Radiological images must be available at the MDM. A photo-
graph of the breast should be available to decide the best sur-
gical strategy. Macroscopic pictures or the histology of special
cases preferably from slides (video microscope or scanned slide)
should be shown to support understanding of difficult histo-
pathological reports.
 Evidence on decisions taken for each patient at the meeting
must be formally recorded. The name of all team members
participating in each meeting must be formally recorded.
 As the patient is usually not present at the MDM and patient
preferences must always be taken into account, and because the
available clinical documents could miss key information, an
MDM decision might, in some cases, be modified at the time of
communication with the patient. For this reason, it is important
that the breast care nurse present knows the patient’s wishes
and expectations to ensure they can be shared at the MDM. The
clinician who informs and discusses with the patient must havethe competence to understand why the patient wants a change
of the recommendation. The reason for change must be docu-
mented in the patient chart and the MDM must be informed.4.6. Breast centre coordinator
The breast centre must have a nominated breast centre coor-
dinator, who can be a healthcare professional from any specialty
within the core team, responsible for the multidisciplinary
approach and the full involvement of breast experts from the core
disciplines and their regular participation in the MDM. The coor-
dinator must ensure there is training and continuing medical ed-
ucation of MDT members; ensure the centre has certain breast
related research; and ensure the centre’s performance is based on
high quality data collection and indicators.
4.7. Communication of diagnosis, treatment plan and waiting times
 A diagnosis must be given to the patient in a face to face meeting
as soon as possible and must not be given by letter or on the
telephone, unless there are exceptional circumstances. A pre-
liminary communication on the diagnosis can be given to the
patient by each specialist according to their competence.
 The MDT recommendation for the treatment plan should be
communicated and discussed with the patient by the clinician
who has initially seen the patient and/or the clinician who will
take primary responsibility for providing the first treatment
modality. This discussionwith the patient is crucial to arrive at a
shared decision which includes the patient’s wishes.
 Healthcare professionals who deal with cancer patients and
their families are recommended to have training in and
knowledge about communication skills.
 A breast care nurse must be available to discuss and give any
additional information to the patient regarding treatment and to
give emotional support. A private room should be available. A
psycho-oncologist should also be available to provide more
advanced support, when needed, to the patient and family.
 Each patient must be fully informed about each step in the
diagnostic and therapeutic pathway and must be given
adequate time to consider the options and make an informed
decision.
 Patients must be allowed to ask for a second opinion [53],
without being penalised in any way.
 Patients must start primary treatment within a maximum of
4e6 weeks from the first diagnostic examination in the breast
centre [54]or first consultation at the breast centre if diagnosed
elsewhere.
 Follow-up should be done within the breast centre according to
the local organisation and patient preference.
 The breast centre should offer to plan imaging investigation
procedures at the same visit.
 The breast centre must give advice and support to the patient
with symptoms and complaints due to hormonal therapy
(osteoporosis, gynaecological problems, etc.), referring the pa-
tient to the appropriate specialist.
 If the patient does not attend the breast centre for follow-up, the
centre should collect follow-up information from elsewhere at
least yearly for its database.4.8. Patient information
 Patients must be offered clear verbal and written information
(leaflets) that describe the diagnostic and treatment options.
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main languages spoken by the population served.
 The leaflets should inform patients about diagnostic and treat-
ment options not offered by the breast centre if they are covered
in current guidelines.
 The centre should provide information on local support groups
and national advocacy organisations and the availability of
group and/or individual psychological support in the centre.
 Patients should be provided with a copy of their rights as out-
lined in the breast cancer resolution of the European Parliament
[7].4.9. Advocacy group/patient volunteer group
It is recommended that the breast centre collaborates with a
local/national advocacy group or patient volunteer group. This
group should collaborate with the centre to offer activities and
projects dedicated to breast centre patients.4.10. Quality control
 The breast centre must have a database to collect data on all
primary and advanced breast cancer patients it treats.
 Data collection is essential to monitor compliance with national
and/or international quality indicators, standards and guide-
lines, and it is also a basis for scientific research at the breast
centre.
 The breast centre must achieve the minimum standard for
EUSOMA’s mandatory quality indicators (as described in
EUSOMA’s quality indicators in breast cancer care, 2017, and
future updates) [54]. If a minimum standard is not achieved the
breast centre must put in place corrective actions and re-
evaluate measures at an agreed date.
 Data must include source of referral, clinical and pathological
diagnosis, treatment, follow-up and clinical outcomes.
 The breast centre must also collect in the database, or in a
separate register, data on all surgical operations performed on
benign disease (with the exclusion of inflammatory disease,
operations for cosmetic reasons or prophylactic surgery).
 The breast centre must have a data manager who works in the
core team under the supervision of a medical doctor designated
by the clinical coordinator. The data manager is responsible for
data collection and analysis and for the organisation of audit
meetings. Data should preferably be collected during the patient
management process. The data manager must inform the breast
centre team about performance quality according to indicators
and about any emerging criticality.
 The breast centre should participate in external benchmarking
activities (comparison of results with those of other centres).
 Breast centres should yearly monitor their outcomes at least on
the following items: local recurrence rate, distant recurrence
rate, sequelae (surgical, radiation and systemic therapy)
aesthetic outcomes, functional outcomes.
 Breast centres are strongly advised to collect and analyse vali-
dated patient reported outcomes (PROs) using validated mea-
surements (patient reported outcome measures, PROMs).
 The centre must have a formal internal review meeting at least
once a year to discuss all performance aspects, i.e. audit results,
continuity of care, organisational and clinical aspects, critical
issues, results of corrective actions, new projects, etc. Core team
members must participate in this meeting, and extended
members should participate. Minutes of the meeting and the list
of participants must be kept.4.11. Education
The breast centre should provide teaching on a local, national or
international basis. Some breast centres may have expertise in
teaching certain subjects, such as reconstruction, screening, pa-
thology/molecular biology, systemic therapies, radiation oncology,
etc. The breast centre should organise at least one teaching course
per year at local, regional, national or international level.
4.12. Research
Research is an essential part of training specialists and un-
derpins every aspect of clinical practice, and breast centres should
be involved in both clinical (i.e. clinical trials) and translational
research. The breast centre should record the numbers of patients
participating in clinical trials and collect details of any other
research activities, such as evaluation of newly introduced tech-
niques. The breast centre should aim to include at least of 5% of
patients in clinical trials each year.
5. Core mdt members
All core MDT members should comply with EUSOMA’s guide-
lines on standards for training specialised health professionals who
deal with breast cancer [55]. All specialists must work according to
protocols and national/international guidelines. All specialists
working in the core team must comply with all specialist related
requirements indicated in the sections below.
5.1. Breast radiology
Breast radiologists.
 The breast centre must have at least 2 dedicated breast
radiologists.
 To be considered a breast specialist, a radiologist must spend at
least 50% of their working time on breast imaging.
 Breast radiologists must be involved in the full assessment of
breast patients, including invasive procedures (core biopsy, ul-
trasound guided, stereotactic vacuum assisted biopsy, etc.).
 Breast radiologists should participate in national or regional
radiology quality assurance schemes.
 Where possible, radiologists involved in the assessment of
breast patients should participate in both breast screening and
symptomatic breast imaging.
 Breast radiologists must read a minimum of 1000 mammog-
raphy cases per year and conduct and read a minimum of 200
breast ultrasound studies (targeted, diagnostic or screening) per
year, and a minimum of 50 breast MRI studies per year.
 Breast radiologists participating in a centralised screening pro-
gramme must have a workload of at least 5000 cases per year
[10].
 Breast radiologists must attend at least one diagnostic clinic per
week for symptomatic patients or further assessment of breast
screening recall.
 Each breast radiologist must perform a minimum of 50 breast
guided interventions per year.
 Double reading of mammograms is encouraged both for
screening and symptomatic mammography when the breast
centre workload is less than 3000 per year; double reading of
breast MRI studies is encouraged when the MRI workload is less
than 200 per year.
 All imaging studies taken outside the centre must be reviewed
by breast centre radiologists.
Fig. 2. Breast cancer centre schematic.
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 The breast radiology team must perform:
◊ Clinical examination
◊ Mammography
◊ Ultrasound and Doppler ultrasound of the breast and axilla
◊ Breast MRI
◊ Core biopsy e free-hand, ultrasound guided, mammography
guided
◊ Vacuum-assisted biopsy under mammographic or breast MRI
guidance. If this is not available within the breast centre,
there must be a formal agreement with a local diagnostic
service
◊ Lesion localisation and bracketing under ultrasound,
mammography, and MRI guidance. If this is not available
within the breast centre, there must be a formal agreement
with a local diagnostic service
◊ Multidisciplinary working should allow all standard in-
vestigations for triple assessment (clinical examination,
mammography and/or ultrasound and biopsy) to be
completed in one visit (but respecting patient’s preferences)
and maximum within 5 working days
 Non-surgical diagnosis by needle biopsy of both benign and
malignant disease is the required standard.
 Palpable lesions must be examined via ultrasound and where
there is an ultrasound correlate, needle biopsy must be done
under ultrasound guidance.
 Needle biopsy must be image-guided for all non-palpable
lesions.
 Image-guided biopsy of non-palpable lesions must be done
under the guidance of an appropriate imaging method; usually,
the same imaging method that was used to establish the diag-
nosis should be used to guide biopsy.
 MRI-guided and mammography guided biopsy can be replaced
by ultrasound guided biopsy; however, in these cases, the
radiologist must ensure that the target identified on ultrasound
corresponds to the target seen on the other imaging method.
 Primary diagnosis using open surgical biopsy is not recom-
mended and only acceptable in exceptional cases.
 Core or vacuum assisted biopsy is the preferred technique for
sampling the breast.
 Core biopsy is also considered the preferred technique for
sampling axillary lymph nodes. Fine needle aspiration cytology
(FNAC) may also be used but requires the availability of a
pathologist who is experienced in interpreting cytology of FNAC
specimens.
 The breast centre must use a single formal imaging risk classi-
fication (e.g. BI-RADS or the European classification).
 The breast centre must collaborate with board certified imaging
experts who carry out interventional radiology techniques, such
as biopsy of metastatic lesions in breast cancer patients.
Imaging equipment.
The breast centre must have:
 Digital mammography
 Stereotactic biopsy attachment and/or dedicated prone biopsy
table
 Methods for mammography guided stereotactic lesion local-
isation and bracketing (wire or clip)
 Ultrasound equipped with a small parts probe 12 MHz and
including Doppler function Methods for ultrasound guided core biopsy
 Methods for ultrasound guided lesion localisation and bracket-
ing procedures
 Breast MRI with1.5 T, dedicated bilateral breast coil; dedicated
equipment for breast immobilisation is strongly encouraged
 Access to MRI-guided vacuum-assisted biopsy and MRI-guided
lesion localisation or bracketing, either in-house or by formal
agreement with an affiliated diagnostic service
 Digital storage of all images (mammograms, ultrasound docu-
mentation, MRI studies)
 Equipment no older than 10 years, unless carefully maintained
and complying with national and/or international standards
 Routine quality control of all equipment used for breast imaging,
according to national protocols and/or European guidelines [10].
If the centre follows a national protocol, this must include
essential points such as assessment of image quality of the
monitors and estimate of the maximum average of glandular
dose.
Breast radiographers.
 Radiographers must have training in breast diagnosis to perform
mammography.
 The breast centremust have at least 2 breast radiographers, each
performing at least 1000 mammograms a year.
 Radiographers should also attend refresher courses at least
every 3 years.
 The breast centre must have protocols on the periodical review
of the technical performance of radiographers.
 Radiographers should participate in regular audit of their
technical performance.
 Breast centres must have protocols on quality control on a daily
basis and must follow guidelines on equipment quality control
as detailed in European guidelines.5.2. Breast pathology
Breast pathologists.
 The breast centre must have at least 2 dedicated breast pa-
thologists (1 of whom should be nominated as the breast pa-
thology lead for the MDT). A pathologist at the breast centre
must spend at least 50% of their working time on breast disease.
 A breast centre pathologist must report on at least 50 early
breast cancer resections per year and should report on at least
100 pre-operative samples (with a mandatory minimum of 50)
and 25 metastatic breast surgical specimens per year.
 Breast pathologists must take part in regional, national and/or
European breast cancer quality assurance schemes.
 Breast pathologists must be familiar with their national and/or
European quality standards and guidelines.
Procedures.
 Breast pathology reports must include histological type (ac-
cording to the WHO Classification of Tumours of the Breast),
grading (according to WHO and EU guidelines: Elston and Ellis
modified Bloom-Richardson grading system), immunohisto-
chemistry (IHC) for diagnosis and for oestrogen, progesterone
and HER2 receptors status. In situ hybridisation (ISH) analyses of
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should also include evaluation of proliferation.
 Ki67 is the preferred marker to assess proliferation [56] but is
not mandatory. Caution is needed about the reproducibility of
IHC for Ki67. If used, the St Gallen International Breast Cancer
Conference has suggested calibrating a common scoringmethod
to achieve high inter-laboratory reproducibility in Ki67 on
centrally stained tissue microarray slides [56].
 For reporting core biopsies, breast pathologists must use the B1-
5 classification as described in European guidelines [10].
Reporting by 2 pathologists of core biopsies is encouraged.
When the patient is treated in an institution different from that
performing the pathological diagnosis, the tumour blocks and
slides must be requested for revision by the breast pathologist.
 Breast tissue samples must be kept as long as possible because
the patient can relapse more than 20 years after the first diag-
nosis. At least 1e2 FFPE blocks most representative of the lesion
must be stored in perfect conditions (controlled temperature,
humidity and parasites) and kept for at least 20 years or ac-
cording to the national law, whichever is longer [57]. An archive
of digital slides should be considered.
Equipment.
 The pathology laboratory must be equipped with microscopes,
cryocut, histoprocessors, microtome staining machines and
immunostainers, and a system for obtaining surgical sample and
slide pictures.
 The equipment must be replaced every 10 years unless carefully
maintained and complying with national and/or international
standards.5.3. Breast surgery
Breast surgeons.
 The breast centremust have at least 2 dedicated breast surgeons
with training in breast surgery.
 Breast surgeons must spend at least 50% of their working time
on breast disease.
 Any breast surgeon at the breast centre must carry out primary
surgery as first operator on at least 50 newly diagnosed breast
cancers a year. If the centre has surgeons in training, those
responsible for supervising trainees might perform fewer than
50 primary cases as first operator. In this case documentation on
their role as second operator supervising trainees must be
available.
 Breast surgeons must be able to perform sentinel lymph node
biopsy in all settings (adjuvant, neoadjuvant, recurrence), all
types of mastectomy (nipple sparing, skin sparing, simple) and
guided surgery for non-palpable tumours, and breast
conserving surgery.
 Breast surgeons must be able to perform risk-reducing tech-
niques for high-risk patients.
 Breast surgeons should advise and where necessary treat
womenwith benign disease, e.g. cysts, fibroadenoma, mastalgia,
inflammatory conditions.
 The breast surgical team should be able to offer level I and II
oncoplastic techniques; breast surgeons should have additional
training in oncoplastic procedures to offer the patient surgical
options.5.4. Breast medical oncology
Breast medical oncologists.
 The breast centre must have at least 2 breast medical oncolo-
gists dedicated to breast cancer. Any breast medical oncologist
at the breast centre must spend 50% of their working time on
breast cancer.
 Breast medical oncologists must treat a minimum of 50 early
and 25 metastatic breast cancer patients per year.
 Breast medical oncologists must supervise systemic therapy and
all decision-making processes for its use.
 Follow-up information on all patients treated with systemic
therapy must be collected, even if patients are treated outside
the breast centre.5.5. Breast radiation oncology
Breast radiation oncologists.
 The breast centre must have at least 2 radiation oncologists
dedicated to breast cancer. Any breast radiation oncologist at the
breast centre must spend at least 50% of their working time on
breast cancer.
 Breast radiation oncologists must treat a minimum of 50 early
breast cancer patients per year. They must also have experience
with palliative treatments.
 Breast radiation oncologists must be competent to determine
the need for techniques such as intensity modulated radio-
therapy (IMRT), image guided radiotherapy (IGRT), cardiac-
sparing radiotherapy, brachytherapy, stereotactic body radio-
therapy (SBRT) and stereotactic radiosurgery.
 Radiation oncologists must be adequately trained in breast
cancer contouring, including regional nodes, and use interna-
tional guidelines such as those developed by the fEuropean
Society for Radiotherapy and Oncology (ESTRO).
 Radiation oncology units must develop and work to an
evidence-based breast radiation therapy clinical protocol that is
reviewed and updated regularly: this should include dose ob-
jectives and constraints for each breast radiation technique.
 It is recommended that all radiation oncology units have a
dedicated breast radiation planning and treatment MDT with
radiation oncologists, radiotherapy physicists, dosimetrists and
therapy radiographers to review and manage challenging cases
including those who cannot be treated within the standard
clinical protocols.
 If the radiation oncology unit is not availablewithin the hospital,
the breast centre must have an agreement with a radiation
oncology unit and breast radiation oncologists must attend the
MDM at the breast centre. In all situations, breast radiation
oncologists must have full access to all patient data regarding
diagnosis and treatment and must be involved in the patient
management plan.
 Follow-up information on all patients treated with radiation
therapy must be collected, even if patients are treated and/or
followed-up outside the breast centre.
Breast radiation technicians.
 It is strongly recommended that the breast centre has dedicated
radiotherapy physicists, dosimetrists and therapy radiogra-
phers. At least 1 medical physicist and 2 radiation therapists/
dosimetrists should have breast cancer as a main interest.
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 The staffing and technical platform should fulfil the re-
quirements described by the EORTC Radiation Oncology Group
[58]. Therefore, the minimum equipment in a radiation
oncology unit must include at least 2 megavoltage units, a CT
scanner dedicated to treatment preparation, and a 3D treatment
planning system. Treatment machines must be equipped with
IGRT tools to verify accurateness of treatment delivery. Equip-
ment must be no older than 12 years, unless carefully main-
tained, upgraded and complying with national and/or
international standards.
 Radiation therapy planning must be carried out according to
optimised (3D) procedures based on anatomically defined vol-
umes, with treatments individualised to 3D target volume def-
initions and contouring. Field-based treatments must be
abandoned.
 The evaluation must be done using tools such as dose volume
histograms, taking into account predefined objectives for the
dose distribution for the target volumes and dose constraints for
organs at risk (including as a minimum the heart and lungs).
Respiratory control should be available and used according to
predefined indications including patient risk factors and doses
to heart and lungs.
 Experience is essential especially in techniques aimed at opti-
mising the homogeneity of dose distribution, including IMRT
and IGRT, partial breast irradiation, and cardiac sparing tech-
niques such as breath-hold.
 Access to 3D brachytherapy is highly recommended.
 SBRT and radiosurgery must be available for treatment of oli-
gometastases and brain metastases.
 The breast centre must have a quality assurance programme for
the entire radiation oncology process, including for the ma-
chines/infrastructure. If specific equipment or working proced-
ures are in place for treating breast cancer patients, theymust be
included in the quality assurance programme. Sufficient
ongoing education for all healthcare professionals is essential.
 Clinical and translational radiation therapy research is
encouraged.5.6. Breast cancer nursing
Breast care nurses.
 The breast centre must have at least 2 breast care nurses dedi-
cating all their working time to breast cancer.
 Breast care nurses must see a minimum of 50 early and 25
metastatic breast cancer patients per year.
 Breast care nurses must be available:
◊ Throughout the patient pathway from diagnosis through
treatment and follow-up, to offer practical advice, emotional
support, explanation of the treatment plan and information
on side-effects [27].
◊ At the time of communication of recurrent or metastatic
disease
◊ At follow-up clinics.
 Breast care nurses must also:
◊ Help to develop protocols, patient pathways, information and
implementation of nursing research [27].
◊ Document their meetings with patients. Record keeping is an
essential part of nursing care [59] and promotes high quality,effective and safe care [60] as the information can be
important for use by other professionals in the MDT [61].6. Extended mdt and other services
6.1. Psychological support/psycho-oncology
 Basic psychological counselling and emotional support must be
provided by a breast nurse or another professional trained in the
psychological aspects of breast cancer care. If psychological
morbidity cannot be dealt with effectively by them, patients
must be referred to a psycho-oncologist or psychiatrist.
 Distress must be recognised, monitored, documented and
treated promptly at all stages of disease. It must be assessed in
all patients using a tool such as a distress thermometer [62].
 A psycho-oncologist must be available throughout the disease
continuum to patients and their families at the breast centre to
help patients deal with common psychological issues in breast
cancer such as fear of recurrence, body image disruption, sexual
dysfunction, treatment-related anxieties, intrusive thoughts
about illness, marital/partner communication, feelings of
vulnerability, existential concerns regarding mortality, fertility,
work-related issues, depression, and, in particular for advanced
breast cancer patients, fear of dying, coping with an incurable
disease and continuous treatment, and feelings of isolation and
guilt.
 A psychiatrist must also be available to patients.6.2. Geriatric oncology
 The breast centre must have access to geriatricians with
oncology experience.
 The role of the geriatric oncologist is to coordinate recommen-
dations to other specialists about the need for personalised in-
terventions for older patients with increased vulnerability to
stressors.
 All older patients (70þ) and patients who appear frail or have
severe comorbidity must be screened with a quick, simplified
frailty screening tool, such as the adapted Geriatric-8 (G8)
screening tool [63,64].
 Frail patients as suggested by the screening tool should undergo
a full geriatric assessment [65]. The assessment can be based on
self-report combined with objective assessments that can be
performed by the breast nurse in collaboration with a physician
(geriatrician/internist/medical oncologist).
 Cognitive impairment affects all aspects of treatmente ability to
consent, compliance with treatment, and risk of delirium e and
screening using tools such as Mini-Cog [66] is advised. A geri-
atrician, geriatric psychiatrist or neurologist should preferably
be involved with impaired patients.
 For frail patients, the geriatrician should be present in the MDT
meeting, or easily available for consultation, to discuss treat-
ment options aligned with the patient’s goals for care.6.3. Oncology pharmacy
 Oncology pharmacists must have experience with antineo-
plastic treatments and supportive care; interactions between
drugs; drug dose adjustments based on age, liver and kidney
function, and toxicity profile; utilisation and monitoring of
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and knowledge of complementary and alternative medicines.
 Oncology pharmacists must liaise with medical oncologists to
discuss cancer treatments, including interactions with other
treatments.
 Oncology pharmacists must be involved in the clinical trials
research of the breast centre.
 Oncology pharmacists must use the European QuapoS guide-
lines (European Society of Oncology Pharmacy) [67]. Oncology
drugs must be prepared in the pharmacy and dispensing must
take place under the supervision of the oncology pharmacist.6.4. Nuclear medicine
 The breast centre must have access to nuclear medicine spe-
cialists for procedures relevant to breast cancer care.
 Sentinel node biopsy (SNB) is included in the standard of care
and must be available. The nuclear medicine physician should
oversee the procedure and identify the nodes in planar and
single photon emission computerised tomography (SPECT) or
SPECT/CT images (recommended if available), as well as
marking the location on the skin, and may collaborate with the
surgeon during surgery in locating the lesion with an intra-
operative probe.
 The nuclear medicine physician must oversee all aspects of PET/
CT for patients who require this procedure either with 18F-FDG
or with other radiotracers, including indications, multidisci-
plinary algorithms and management protocols.68,69,70,71,72
 There is evidence of the efficacy of 18F-FDG-PET/CT in selected
clinical indications in breast cancer, such as staging of high-risk
patients, treatment planning, response monitoring, and detec-
tion of recurrent disease [68e72] 18F-FDG-PET/CT should not be
used for surveillance for recurrent disease in asymptomatic
patients.
 Conventional nuclear medicine such as bone scan and cardiac
multigated acquisition (MUGA) should also be available.
 Equipment should preferably be onsite, be less than 10 years old,
unless carefully maintained and complying with national and/or
international standards, ready for radiation treatment planning,
and have an integrated picture archiving and communication
system/radiology information system (PACS/RIS) and updated
workstations.
 The nuclear medicine department must be able to perform daily
verification of protocols and to react accordingly. Quality-
assurance protocols must be in place. An option for ensuring
the high quality of PET/CT scanners is provided by the European
Association of Nuclear Medicine (EANM) through EARL
accreditation.6.5. Physiotherapy
 There must be at least 2 physiotherapists with expertise in
lymphatic drainage for the treatment of lymphoedema and its
related sequelae, and to ensure good shoulder mobility.
 Physiotherapists with expertise in rehabilitation of metastatic
patients with sequelae of bone or brain metastases and their
treatments must be available for breast centre patients.
 A rehabilitation programme for cancer patients who require
assistance in the recovery of functional status after treatment
must be available.
 Physiotherapists must collaborate with the palliative care ser-
vice and with medical oncologists and breast nurses at the
breast centre.6.6. Breast plastic surgery
The role of breast plastic surgeons depends on the organisation
of the breast centre. In most centres, microsurgery reconstruction
techniques are performed by breast plastic surgeons as part of the
breast surgical team. If necessary the breast centre must make ar-
rangements with 1 or 2 breast plastic surgeons with a special in-
terest in breast reconstructive and reshaping techniques.
6.7. Interventional radiology
The breast centre must have access to interventional radiologist
expertise. Bone metastases carry an important risk of developing
skeleton-related events that impact quality of life. Besides surgery
and radiotherapy, percutaneous image-guided cementoplasties/
closed internal fixation/thermal ablation have a growing role in the
treatment of these metastases.
6.8. Self-image support
 There must be a breast prosthesis fitting service within the
breast centre or referral to a service outside the centre.
 There must be counselling about hair prosthesis and referral to
recommended services.6.9. Palliative care
Palliative care, as defined by the World Health Organisation,
applies not only at end of life but throughout cancer care. Palliative
care means patient and family-centred care that enhances quality
of life by preventing and treating physical, psychosocial and spiri-
tual suffering early in the course of advanced disease [73e75].
Palliative care services include general palliative care provided
by the oncology professionals at the breast centre who are
responsible for breast cancer care and specialised palliative care
provided by a multidisciplinary palliative care team [76e78]. Close
collaboration between the breast centre and palliative care teams is
crucial.
 There must be a specialist palliative care team that provides
expert outpatient and inpatient care including specialist physi-
cians and nurses, working with social workers, chaplains,
physiotherapists, occupational therapists, dieticians, pain spe-
cialists and psycho-oncologists. In practice:
◊ The breast centre team, in particular medical oncologists and
breast nurses, is usually responsible for basic palliative care
such as symptom control and screening for disease and
treatment related symptoms and suffering
◊ Patients with severe symptom burden or unmet physical,
psychosocial or spiritual needs must be referred to a
specialist palliative care team, irrespective of the cancer-
specific treatment plan [79].
 The most common physical, psychosocial and spiritual symp-
toms/problems and functional impairments must be assessed in
all patients using tools such as the Edmonton Symptom
Assessment Scale (ESAS) [80] or EORTC questionnaire on quality
of life in palliative cancer care patients (QOL-C15-PAL e https://
qol.eortc.org/questionnaire/qlq-c15-pal).
 The palliative care team must have good knowledge of cancer
disease and cancer treatments including adverse effects of
treatment and rehabilitation needs to be able to offer holistic
care in collaboration with other professionals. Early palliative
care should be provided in conjunction with cancer specific
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pain and dyspnoea, and for psychosocial and spiritual care.
 The palliative care team must support family members and
carers, and have experience of taking care of younger patients
and their families.
 Palliative care specialists and oncologists must aspire to meet
the standard of ESMO Designated Centres of Integrated
Oncology and Palliative Care (http://www.esmo.org/Patients/
Designated-Centres-of-Integrated-Oncology-and-Palliative-
Care).
 To ensure continuity of care at home, the palliative care team
must workwith primary or community care providers or be able
to provide direct care at home, and must provide end-of-life
care.6.10. Clinical genetics
 The breast centre must have a dedicated clinical geneticist
responsible for a genetics clinic, or an agreement with a hospital
where this service is available.
 The clinical genetics service must offer:
◊ Diagnostic surveillance with protocols for high-risk women
including screening MRI according to the level of risk
◊ Risk assessment counselling and testing for BRCA mutations
in high-risk groups in accordance with national and/or in-
ternational protocols
◊ Genetic testing for BCRA mutations; a molecular geneticist
must be accessible for consultation
◊ Protocols for risk reduction surgeries and chemoprevention
◊ Psychological support to facilitate an accurate perception of
risk and its acceptance, to assure adherence to surveillance
plans, and to support the patient with complex decision-
making
◊ Registration of patient data in an appropriate database and
involvement in research
◊ BRCA mutation testing for metastatic breast cancer patients,
in view of the potential clinical implications. At present, no
other genes are recommended for testing in the metastatic
setting, including with any next generation sequencing (NGS)
test [20].6.11. Prevention
A growing body of evidence documents the effectiveness of
physical activity and a correct diet for a variety of outcomes in
breast cancer survivors. There is evidence from randomised trials
that physical activity in breast cancer patients has positive effects
on physical functions, psychological outcomes and quality of life
[81,82]. There is evidence from well conducted observational
studies and meta-analyses [83,84] that physical activity reduces
overall and cause specific mortality in breast cancer patients
[85e87]. There is preliminary evidence that physical activity pro-
duces beneficial effects on biomarkers linked to better prognosis
and on local recurrence [88e90]. A World Cancer Research Fund
report recommends that breast cancer survivors follow the same
physical exercise and diet recommendations as for the general
population [91].
 Breast centres must offer or recommend physical activity and
dietary intervention programmes to their patients; compliance
with such programmes should be assessed and encouraged
during regular follow-up visits. Lifestyle counselling should include home-based exercise [92]
and is an important supportive role for the breast care nurse
[93].
Appendix 1. Supporting evidence and information
1.1. Critical mass/volume requirements/mdt working
 The concept of the multidisciplinary breast centre ewhich may
also treat other breast conditions as well as cancere is nowwell
established in several countries in Europe and North America.
There are some national specifications that may complement
the one set out in this paper.
 The evidence base is partly built on procedures by specialist
breast surgeons. For example, in 1996 a study comparing sur-
vival outcomes by specialist and non-specialist breast cancer
surgeons in Scotland showed that the absolute 5 year survival
rate was 9% higher and the 10 year survival 8% higher for pa-
tients cared for by specialist surgeons, with a relative reduction
in risk of dying of 16% [94]. A later paper from the United States,
in 2003, found a similar absolute benefit, of 7% at 5 years, and a
relative risk reduction of 33%, of treatment by specialist surgical
oncologists [95].
 Hospital and surgical volume have also been confirmed as
positive factors. A systematic review of the volume-outcome
relationship with breast cancer surgery found that improved
survival was significantly associatedwith high volume providers
[96]. Another study found that higher surgeon and hospital
volume significantly predicted lower subsequent re-operation
after breast conserving surgery and after adjustment for socio-
demographic and clinical variables [97]. A recent study from
the United States reported that treatment at high volume cen-
tres is associated with improved survival for breast cancer pa-
tients regardless of stage, and that high case volume could serve
as a proxy for the institutional infrastructure required to deliver
complex multidisciplinary breast cancer treatment [98].
 Looking at multidisciplinary aspects, an observational cohort
study evaluated the effects on breast cancer survival on nearly
14,000 women in Scotland, and found MDT working was asso-
ciated with a 18% lower breast cancer mortality at 5 years [99].
By comparing an area where MDT working was introduced with
areas that had not implemented it, the authors found that it
probably improves patient outcomes by influencing various
aspects of care, such as adherence to guidelines, nurse educa-
tion, increased surgical volume and experience, and improved
interdisciplinary working. A study in Taiwan that compared
those receiving MDT treatment with those without found that
MDT intervention significantly increased the breast cancer
survival rate [100]. A population study from a region in Germany
suggested there may be evidence of increasedmortality if breast
cancer patients do not receive guideline compatible treatment
[101].
 There are studies that report changes in treatment plans
following MDT discussion. In single institution studies in the
United States and Canada, a second evaluation of patients
referred to a multidisciplinary tumour board led to changes in
the recommendations for surgical management in 77 of 149 of
patients studied (52%) [102], and management plans changed in
41% of cases presented, the majority due to new/clarified diag-
nostic information [103]. A UK study found that MDT meetings
enable cross-speciality interrogation of requests for prophylac-
tic mastectomy, minimise unnecessary surgery and restrict
mastectomy to those likely to derive maximum benefit [104].
 A global survey, completed by principal investigators from 39
countries participating in a phase III trial, showed that
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two-thirds of centres in Eastern/Western Europe to only a
quarter in South America and a third in Asia [105]. But a review
of breast cancer MDT working notes about this survey that most
centres that reported having mandatory MDT care lacked na-
tional or regional guidelines regarding composition or practice
of MDT work to ensure consistency of provision (only 19% re-
ported having such guidelines) [106].
 Among the most compelling recent evidence is a study on
Germany’s breast cancer services. It reports that low-volume
hospitals with 30 cases/year had a statistically significant 3-
fold increased risk of death after breast conserving treatment
and a significantly increased the likelihood of postoperative
complications after both breast conserving treatment and breast
ablative therapy [107]. Also noted was that length of stay was
shorter and non-routine discharge was lower at high-volume
hospitals and that the likelihood of receiving beast conserving
surgery was significantly higher at high-volume hospitals.
Another study in Germany found that adherence to breast
cancer surgery quality processes is higher in hospitals that treat
more cases [108].1.2. PATHWAYS
 Care for all cancer patients should be organised in pathways that
cover the patient’s journey, and pathways must correspond to
current national and European evidence-based clinical practice
guidelines on diagnosis, treatment and follow-up. The European
Pathway Association defines a care pathway as “a complex
intervention for the mutual decisionmaking and organisation of
care processes for a well-defined group of patients during a
well-defined period”. This broad definition covers terms such as
clinical, critical, integrated and patient pathways that are also
often used See http://e-p-a.org/care-pathways and also the
WHO framework on integrated people-centred health services,
http://www.who.int/servicedeliverysafety/areas/people-
centred-care.
 There are many examples of care pathways for breast cancer
given the pioneering role this cancer has played in developing
multidisciplinary care. Examples are from the National Institute
for Health and Care Excellence (NICE) in the UK [109,110] and
Cancer Council Australia [111]. A paper from the UK also gives a
good example and emphasises the role that care pathways play
with the MDT as the integral part of the system [112]. The UK
was one of the first countries to establish the value of MDTs for a
cancer type, and together with defined care pathways has been
instrumental in addressing variations in outcomes among breast
units and regions in the country. A key point reiterated is that
the management of breast cancer patients is a complex under-
taking, requiring coordination among specialist team members
to enable high-quality individualised care.1.3. Patient advocacy
Patient advocacy for breast cancer is the most widely available
and well organised of any cancer type in the world. The principal
European-wide organisation is Europa Donna, which counts more
than 50 national member organisations or representatives in
Europe (https://www.europadonna.org). Europa Donna has been
instrumental in lobbying at European level for the adoption of
declarations and resolutions on universal screening and multidis-
ciplinary breast cancer services in the European Union. Many Eu-
ropean countries have dedicated advocacy groups, such as BreastCancer Care (https://www.breastcancercare.org.uk) and Breast
Cancer Now (http://breastcancernow.org) in the UK, Brustkrebs in
Germany (http://brustkrebsdeutschland.de), and the Dutch Breast
Cancer Association (https://borstkanker.nl).
There is a need to develop more advocacy and support for
advanced/metastatic breast cancer patients. This can be achieved
by dedicated advocacy groups, such as in the US with MetaVivor
and the Metastatic Breast Cancer Network, or through the devel-
opment of dedicated resources within advocacy groups. Examples
of the latter are the recently launched MBC advocacy programme
and website of Europa Donna (https://mbc.europadonna.org) and
the MBC programmes of Komen (http://www.komen.org) and
Breast Cancer Network Australia (http://www.bcna.org.au). The
recently created ABC Global Alliance is amultistakeholder platform,
coordinated by ESO (European School of Oncology), and is dedi-
cated to advanced/metastatic breast cancer patients globally
(http://www.abcglobalalliance.org).1.4. Accreditation/certification, audit and quality
There is wide evidence of the benefit of external audits (i.e.
certification or accreditation) for improved performance and out-
comes in many fields, including medicine in general and oncology
in particular.
There are a variety of methods for organisational quality
assessment, which can differ with respect to several characteristics,
e.g. voluntary versus compulsory, and collegial (driven by pro-
fessionals) versus regulatory (driven by governments). Another
important difference is between assessment of organisational and
quality systems aspects and those that focus on clinical aspects or
specialty services [113].
All breast centresmust consider a voluntary certification process
at national and/or European level. Such schemes include the
following.
 A voluntary certification scheme (accredited by Accredia) based
on the EUSOMA requirements has been developed and
accredited (http://www.breastcentrescertification.com). It
evaluates the patient pathway in terms of services, health pro-
fessionals, equipment, organisation, and data collection. Ayearly
report is issued to monitor compliance with EUSOMA’s quality
indicators.
 The German Cancer Society certification system for cancer
centres in Germany was launched in 2003, initially for breast
cancer (https://www.krebsgesellschaft.de/gcs/german-cancer-
society/certification.html). It is a voluntary initiative that has
been subject to evaluation in several papers and now covers
breast cancer centres in Austria, Switzerland and northern Italy,
as well as Germany. The German Cancer Society’s report for the
audit year 2017 details the performance of certified breast
cancer centres. It covered 275 clinical sites and includes provi-
sion of psycho-oncology and social services counselling [114].
 The National Accreditation Program for Breast Centres (NAPBC)
is a programme run by the American college of Surgeons and
made its first award in 2008 (https://www.facs.org/quality-
programs/napbc). It accepts applications from centres outside
of the US.
 Organisation of European Cancer Institutes (OECI) accreditation
is a European accreditation and quality improvement pro-
gramme for cancer centres and comprehensive cancer centres
which evaluates the whole quality system in cancer including
research, and which can help to integrate breast centres within
the wider cancer centre infrastructure (https://www.oeci.eu)
[115]. The programme was launched in 2008 and the quality
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Society for Quality in Healthcare (ISQua).
European Commission Initiative on Breast Cancer.
The European Commission Initiative on Breast Cancer (ECIBC,
http://ecibc.jrc.ec.europa.eu) comprises two working groups. The
Guideline Development Group is developing a new edition of the
European guidelines for quality assurance in breast cancer
screening and diagnosis, and the Quality Assurance Scheme
Development Group (QASDG) is developing a set of voluntary
quality and safety requirements for breast cancer services in
Europe.
QASDG has defined the care pathway for breast cancer screening
and care, the interventions and services to be considered, the
quality domains to be included and how the scheme can be
implemented in Europe. Importantly, QASDG is taking a modular
approach to adapt to different breast service configurations in
Europe. Outputs, expected in 2020, will be a quality assurance
manual, a self-assessment tool and a quality indicators calculator.
Other national and international quality examples and projects.
 NICE in the UK updated its quality standard for breast cancer
services in 2016 [116]; it comprises 6 statements, and NICE
considered that others previously listed are no longer priorities
for improvement (such as on ultrasound evaluation of the axilla,
oncoplastic breast conserving surgery, those with early invasive
cancer are offered the same care regardless of age). As such the
current quality standard is a guide to issues that may also be
identified in other countries as priorities. They are:
◊ People with suspected breast cancer referred to specialist
services are offered the triple diagnostic assessment in a
single hospital visit
◊ People with biopsy proven invasive breast cancer or ductal
carcinoma in situ (DCIS) are not offered a preoperative MRI
scan unless there are specific clinical indications for its use
◊ People with ERþ, HER2-and lymph node-negative early
breast cancer who are at intermediate risk of distant recur-
rence are offered gene expression profiling with Oncotype DX
◊ People with newly diagnosed invasive breast cancer and
those with recurrent breast cancer (if clinically appropriate)
have ER and HER2 status of the tumour assessed
◊ People with breast cancer who develop metastatic disease
have their treatment and care managed by an MDT
◊ People with locally advanced, metastatic or distant recurrent
breast cancer are assigned a key worker.
 The National Clinical Audit Programme in the UK published the
first National Audit for Breast Cancer in Older Patients (NABCOP)
in 2017, on services in England andWales (https://www.nabcop.
org.uk). The need for the audit was based on concern that de-
livery of care by NHS services in the UK has found breast cancer
services have a non-standard and variable approach to the
management of older patients. The report says that breast
cancer units should review patient and carer involvement with
decision making, develop protocols to assess the health of older
patients, identify patients who could benefit from specialist
older person teams, and define the contributions of specialists
such as nurses and palliative care doctors for care of older
people, among other recommendations.
 In the Netherlands, the NABON Breast Cancer Audit (NBCA)
started collecting data from all Dutch hospitals from 2011 with
the aims of nationwide evaluation of quality parameters, eval-
uation of guideline adherence, and weekly feedback to partici-
pating institutions. After 4 years of auditing, patients being
discussed in pre- and post-operative multidisciplinary team
meetings improved (2011: 83% and 91%; 2014: 98% and 99%,respectively) [117]. Tumour margin positivity rates after breast-
conserving surgery for invasive cancer requiring re-operation
were consistently low, but other indicators, for example, the
use of an MRI scan prior to surgery or immediate breast
reconstruction following mastectomy showed considerable
hospital variation.
 The mission of the Breast Centres Network is to promote syn-
ergy among breast units by connecting specialists and personnel
working in the field, and to help breast cancer patients find the
right place for care or for a second opinion (http://www.
breastcentresnetwork.org). It is run by the European School of
Oncology and currently lists more than 220 breast units globally.1.5. Education and training
It is essential that each breast cancer centre provides profes-
sional clinical and scientific education on the disease and that at
least one person is responsible for this programme. Healthcare
professionals working in breast cancer must also receive training in
psychosocial oncology, palliative care, rehabilitation and commu-
nication skills. Such training must also be incorporated into
specialist postgraduate and undergraduate curriculums for physi-
cians, nurses and other professionals. An expert group at the Eu-
ropean Commission has endorsed a recommendation for
multidisciplinary training of cancer specialists to improve the value
of MDTs and patient care [118].
Breast cancer training varies greatly among European countries
and there is a need for multidisciplinary initiatives such as the
Certificate of Competence in Breast Cancer from the European
School of Oncology, which started in 2017 [119]. There is a great
variability in breast cancer surgery training in Europe and it is
imperative to develop quality standards for breast cancer surgery
training to ensure that patients receive standardised and certified
surgical management regardless of the country in which they are
treated [120]. A curriculum for breast care nurses has been intro-
duced by the European Oncology Nursing Society (EONS) [27].
1.6. Clinical research and registries
 Centres treating breast cancer should have clinical research
programmes (either their own research or as a participant in
programmes led by other centres/cooperative groups). The
research portfolio should have both interventional and non-
interventional projects and include academic research. The
MDT must assess all new patients for eligibility to take part in
academic and industry sponsored clinical trials at the centre or
in research networks.
 Collaboration within national and/or international European
academic research networks or cooperative groups is strongly
recommended since high-quality clinical and translational
research can no longer be performed in isolated centres. Breast
cancer research is well organised worldwide, with most coun-
tries having at least one national breast cancer group and with
BIG (Breast International Group, http://www.
bigagainstbreastcancer.org), which is an umbrella organisation
of national and international breast cancer cooperative groups.
BIG has longstanding collaboration with North American breast
cancer groups for large global projects.
 In countries where clinical trials are less available, centres
treating breast cancer should engage with policymakers to
investigate referring patients to other countries (as proposed
with European Reference Networks) and should be prepared to
participate in clinical trials from an organisational standpoint.
Researchers at other centres should be considered as part of the
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participation. Generally, pan-European action should be taken
to increase participation of breast cancer patients in clinical
trials (both industry-sponsored and academic), and internet
access to local clinical trial databases should be developed.
 Older adults are currently underrepresented in cancer clinical
trials despite having a disproportionate burden of disease.
Strategies to increase the participation of older adults must be
implemented and trials designed to take their needs into
account.
 Other underrepresented breast cancer patients in clinical trials
are male breast cancer patients and young premenopausal
women. Strategies to increase their participation must be
implemented.
 Correlative biomarker research is a crucial part of all phases of
clinical studies and requires close cooperation with between
basic and clinical research groups, as well as the availability of
high-quality certified biobanks, at local, national or interna-
tional level.
 Cancer control plans must include high-quality population and
clinical cancer registries for breast cancer to inform both
research and improve quality of care. A population example is
Nordcan (http://www-dep.iarc.fr/NORDCAN), which includes
breast cancer in 50 cancer types in the Nordic countries; and for
screening, CANSCREEN5 (http://canscreen5.iarc.fr). Important
bodies are the International Association of Cancer Registries
(IACR) and the European Network of Cancer Registries (ENCR),
and the European Commission’s Joint Research Centre (JRC),
which with ENCR is working on harmonisation of data and
registration processes.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.breast.2020.02.003.
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